← Oncology Approval Tracker

FDA DECISION ·

Keytruda Qlex

pembrolizumab + berahyaluronidase alfa-pmph · Merck

FDA approvalNew formulationMultiple solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Subcutaneous treatment for adults and, where the corresponding intravenous solid tumor indication permits, children age 12 years or older with an eligible pembrolizumab indication, with the separately accelerated TMB-high use tracked on its own.

LAMPGEN ANALYSIS

Why it matters

The subcutaneous formulation extends approved solid tumor uses to an alternate route, supported by pharmacokinetic comparability.

What research teams should watch

Update route-specific order sets and scheduling; check each underlying indication and dosing schedule before use.

PRIMARY RECORDS

Sources